Cerebrovasc · reinforce

Vascular diseases
Cerebrovasc · reinforce

WHY Cellpia

Stem cell cerebrovascular strengthening procedure

Stem cell cerebrovascular strengthening procedure involves transplanting stem cells and induced to migrate into blood vessels. Stem cells are supplied directly to the cerebral blood vessels through the carotid artery to strengthen blood vessels, create new blood vessels where they are needed, providing smooth aid when supplying oxygen and nutrients. It is effective in preventing cerebrovascular disease.

Autologous stem cells separated and concentrated without culture, same-day treatment!

  • Old stem cells
  • New stem cells

Stem cell cerebral blood vessels strengthening Cerebrovascular disease is one of the three leading causes of death in Korea. It is a disease that causes problems with the blood vessels in the brain that supply blood to the brain. More than 50% of patients with cerebral infarction and about 70% of patients with cerebral hemorrhage have hypertension. The development risk is also high in the case of diabetes or hyperlipidemia.

Stem cell brain health promotion Stem cells are effective in preventing brain diseases. The cells help to regenerate nerve cells that are closely related to brain health, improve several symptoms that occur in the brain, provide aids in the regeneration of damaged tissue, promote the activation of new brain cells and the strengthening effect of blood vessels, and help to limit your daily life or slow the progression to dementia.

Diseases that can be prevented by stem cell cerebrovascular strengthening treatment

In order to prevent brain damage in advance, cerebrovascular management is important. In addition to the effect of preventing brain damage, stem cells have been shown to have a positive effect on symptom improvement in epilepsy (epileptic) patients.

In Dr. Osman’s ‘Can Stem Cells be Used to Treat Epilepsy’ study published in News Medical, a UK medical journal in 2019, it is stated that seizure frequency has been reduced in clinical trials using autologous mesenchymal stem cells on 22 epilepsy patients.